<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282724</url>
  </required_header>
  <id_info>
    <org_study_id>BT0500INT001</org_study_id>
    <nct_id>NCT00282724</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg od and 150 mg od) Given During 12 Weeks in Lamellar Ichthyosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Lamellar ichthyosis is a congenital disease of the skin with a generalized scaling. The
      primary activity of liarozole is considered to be the inhibition of the degradation of a
      substance called retinoic acid, which is the principal endogenous regulator of growth and
      differentiation of epithelial tissues in mammals. The current study intends to evaluate the
      efficacy and safety in patients with lamellar ichthyosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lamellar ichthyosis is an autosomal recessive disorder that is apparent at birth and is
      present throughout life. Although the disorder is not life threatening, it is quite
      disfiguring and causes considerable psychological stress to affected patients. Prevalence is
      less than 1 case per 300,000 individuals. Treatment is mainly symptomatic i.e. emollients
      with or without keratolytic agents. Treatment with systemic retinoids is reserved for those
      patients, refractory to conventional therapy, because of the long-term adverse effects and
      teratogenicity of systemic retinoids.

      Liarozole may provide a new concept for the treatment of this condition. Because of its
      mechanism of action, retinoic acid (RA) levels will only be increased in tissues that are
      targets for RA production.

      The proposed Phase II/III study intends to evaluate the efficacy of liarozole compared with
      placebo, in patients with lamellar ichthyosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Investigator's Global Assessment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Scaling Score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity scores of other symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <enrollment type="Actual">98</enrollment>
  <condition>Ichthyosis, Lamellar</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liarozole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either sex aged 14 years or older.

          -  Clinical diagnosis of lamellar ichthyosis

          -  Women of childbearing potential should use appropriate contraception

          -  Women of childbearing potential should have a negative pregnancy test at screening
             visit.

          -  Subjects are, except for their lamellar ichthyosis, in good general health.

          -  Subjects and legal representative(s), if applicable, signed informed consent.

        Exclusion Criteria:

          -  Subject is receiving topical (except emollient), UV treatment or systemic treatment
             for ichthyosis.

          -  Subject is pregnant or breast feeding.

          -  History or suspicion of alcohol or drug abuse.

          -  Significant co-existing diseases.

          -  Clinically significant abnormal ECG

          -  History of hypersensitivity to retinoids or any of the ingredients in the trial
             medication.

          -  Clinically relevant laboratory abnormalities at screening.

          -  Use of immune-suppressive drugs including topical or systemic corticosteroids.

          -  Participation in an investigational trial 30 days prior to the start of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koen van Rossem, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Barrier Therapeutics/ Stiefel, a GSK Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geel</name>
      <address>
        <city>Geel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Justine</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newlab Clinical Research Inc.</name>
      <address>
        <city>St John</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dermatologico</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu CHU</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomesa Fachklinik</name>
      <address>
        <city>Bad Salzschlirf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dueren</name>
      <address>
        <city>Dueren</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universität</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Mangiagalli e Regina Elena</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Dermopatico dell'Immacolata</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet Universitetsklinikk</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Dominican Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Van Wauwe JP, Coene MC, Goossens J, Cools W, Monbaliu J. Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther. 1990 Jan;252(1):365-9.</citation>
    <PMID>2299598</PMID>
  </reference>
  <reference>
    <citation>Van Wauwe J, Van Nyen G, Coene MC, Stoppie P, Cools W, Goossens J, Borghgraef P, Janssen PA. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther. 1992 May;261(2):773-9.</citation>
    <PMID>1374473</PMID>
  </reference>
  <reference>
    <citation>Van Wauwe J, Coene MC, Cools W, Goossens J, Lauwers W, Le Jeune L, Van Hove C, Van Nyen G. Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. Biochem Pharmacol. 1994 Feb 11;47(4):737-41.</citation>
    <PMID>8129749</PMID>
  </reference>
  <reference>
    <citation>Kang S, Duell EA, Kim KJ, Voorhees JJ. Liarozole inhibits human epidermal retinoic acid 4-hydroxylase activity and differentially augments human skin responses to retinoic acid and retinol in vivo. J Invest Dermatol. 1996 Aug;107(2):183-7.</citation>
    <PMID>8757760</PMID>
  </reference>
  <reference>
    <citation>Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol. 1995 Sep;133(3):426-32.</citation>
    <PMID>8546999</PMID>
  </reference>
  <reference>
    <citation>Berth-Jones J, Todd G, Hutchinson PE, Thestrup-Pedersen K, Vanhoutte FP. Treatment of psoriasis with oral liarozole: a dose-ranging study. Br J Dermatol. 2000 Dec;143(6):1170-6.</citation>
    <PMID>11122017</PMID>
  </reference>
  <reference>
    <citation>Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CE. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2001 Oct;145(4):546-53.</citation>
    <PMID>11703279</PMID>
  </reference>
  <reference>
    <citation>Lucker GP, Heremans AM, Boegheim PJ, van de Kerkhof PC, Steijlen PM. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol. 1997 Jan;136(1):71-5.</citation>
    <PMID>9039298</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>September 23, 2011</last_update_submitted>
  <last_update_submitted_qc>September 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lamellar ichthyosis</keyword>
  <keyword>Liarozole</keyword>
  <keyword>Investigator's Global Assessment</keyword>
  <keyword>Scaling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ichthyosis</mesh_term>
    <mesh_term>Ichthyosis, Lamellar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liarozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

